

**Louisiana Department of Health and Hospitals
Medicaid Pharmaceutical and Therapeutics Committee
628 North Fourth Street
Baton Rouge, LA
Bienville Building
Room #118
May 4, 2016
9:00 AM
DRAFT**

- I. Call to Order.....Marty McKay
- II. Parliamentary BusinessMarty McKay
 - A. Introduction of Members/Roll Call
 - B. Approval of October 28, 2015 Meeting Minutes
 - C. P & T Bylaws – Proposed Amendment
- III. Ethics Reminders..... Kim Sullivan
- IV. Reports.....Melwyn Wendt
 - A. Prior Authorization Monthly Report
 - B. PDL Reflecting October 28, 2015 P&T Committee Recommendations
 - C. Louisiana Medicaid Preferred Drug List Program Overview and Results Report – January 2016
- V. New Business..... Nina Bandali
 - A. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony
 - 1. Analgesics, Narcotics Long
 - 2. Analgesics, Narcotics Short
 - 3. Angiotensin Modulator Combinations
 - 4. Angiotensin Modulators
 - 5. Antibiotics, GI
 - 6. Antibiotics, Inhaled
 - 7. Antibiotics, Topical
 - 8. Antibiotics, Vaginal
 - 9. Anticoagulants
 - 10. Antiemetic/Antivertigo Agents
 - 11. Antifungals, Oral
 - 12. Antifungals, Topical
 - 13. Antimigraine Agents, Triptans
 - 14. Antiparasitics, Topical
 - 15. Antivirals, Oral - New
 - 16. Antivirals, Topical
 - 17. Beta-Blockers
 - 18. Bladder Relaxant Preparations
 - 19. Bone Resorption Suppression and Related Agents
 - 20. BPH Treatments
 - 21. Calcium Channel Blockers
 - 22. Cephalosporins and Related Antibiotics
 - 23. Fluoroquinolones, Oral
 - 24. GI Motility, Chronic - New
 - 25. Growth Hormone
 - 26. H. Pylori Treatment - New

27. Hepatitis C Agents
28. Hypoglycemics, Incretin Mimetics/Enhancers
29. Hypoglycemics, Insulin and Related Agents
30. Hypoglycemics, Meglitinides
31. Hypoglycemics, SGLT2
32. Hypoglycemics, Sulfonylureas - New
33. Hypoglycemics, TZD
34. Immunosuppressives, Oral - New
35. Lincosamides/Oxazolidinones/Streptogramins
36. Lipotropics, Other
37. Lipotropics, Statins
38. Macrolides/Ketolides
39. Multiple Sclerosis Agents
40. Nitrofurans Derivatives - New
41. Opiate Dependence Treatments
42. PAH Agents, Oral and Inhaled
43. Pancreatic Enzymes
44. Phosphate Binders
45. Pituitary Suppressive Agents, LHRH
46. Platelet Aggregation Inhibitors
47. Proton Pump Inhibitors
48. Skeletal Muscle Relaxants
49. Tetracyclines
50. Ulcerative Colitis Agents
51. Vasodilators, Coronary - New

- VI. New Single Drug Reviews from Fall Classes.....Nina Bandali
 1. Antihyperuricemics – Mitigare
 2. Antipsychotics - Aristada
 3. Antipsychotics – Vraylar
 4. COPD Agents – Spiriva Respimat
 5. COPD Agents – Utibron Neohaler
 6. COPD Agents – Seebri Neohaler
 7. Cytokine and CAM Antagonists – Xeljanz XR
 8. Intranasal Rhinitis Agents - Ticanase
 9. Progestational Agents - Makena
 10. Steroids, Topical High – Dermacinrx Silazone
 11. Steroids, Topical High – Silazone – II
 12. Stimulants and Related Agents – Quillichew ER
 13. Stimulants and Related Agents – Dyanavel XR
- VII. Other Business
- VIII. Next Steps
 - A. Proposed Therapeutic Classes to be Reviewed at Next Meeting
- IX. Next Meeting Date – October 26, 2016 or November 2, 2016
- X. Public Testimony